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Abstract
The European Working Group on Sarcopenia in Older People (EWGSOP) developed a practical clinical deﬁnition and
consensusdiagnosticcriteriaforage-relatedsarcopenia.EWGSOPincludedrepresentativesfromfourparticipantorganisations,
i.e. the European Geriatric Medicine Society, the European Society for Clinical Nutrition and Metabolism, the International
AssociationofGerontologyandGeriatrics—EuropeanRegionandtheInternationalAssociationofNutritionandAging.These
organisations endorsed the ﬁndings in the ﬁnal document.
The group met and addressed the following questions, using the medical literature to build evidence-based answers: (i) What
is sarcopenia? (ii) What parameters deﬁne sarcopenia? (iii) What variables reﬂect these parameters, and what measurement
tools and cut-oﬀ points can be used? (iv) How does sarcopenia relate to cachexia, frailty and sarcopenic obesity?
For the diagnosis of sarcopenia, EWGSOP recommends using the presence of both low muscle mass + low muscle function
(strength or performance). EWGSOP variously applies these characteristics to further deﬁne conceptual stages as ‘presarco-
penia’, ‘sarcopenia’ and ‘severe sarcopenia’. EWGSOP reviewed a wide range of tools that can be used to measure the speciﬁc
variables of muscle mass, muscle strength and physical performance. Our paper summarises currently available data deﬁning
sarcopenia cut-oﬀ points by age and gender; suggests an algorithm for sarcopenia case ﬁnding in older individuals based on
measurements of gait speed, grip strength and muscle mass; and presents a list of suggested primary and secondary outcome
domains for research.
Once an operational deﬁnition of sarcopenia is adopted and included in the mainstream of comprehensive geriatric assess-
ment, the next steps are to deﬁne the natural course of sarcopenia and to develop and deﬁne eﬀective treatment.
Keywords: sarcopenia elderly muscle strength muscle mass physical performance
412Sarcopenia as a geriatric syndrome
A grave change associated with human ageing is progressive
decline in skeletal muscle mass, a downward spiral that may
lead to decreased strength and functionality. In 1989, Irwin
Rosenberg proposed the term ‘sarcopenia’ (Greek ‘sarx’ or
ﬂesh + ‘penia’ or loss) to describe this age-related decrease
of muscle mass [1, 2]. Sarcopenia has since been deﬁned as
the loss of skeletal muscle mass and strength that occurs
with advancing age [3]. However, a widely accepted deﬁn-
ition of sarcopenia suitable for use in research and clinical
practice is still lacking.
Geriatric syndromes are common, complex and costly
states of impaired health in older individuals. Geriatric syn-
dromes result from incompletely understood interactions of
diseaseandageonmultiplesystems,producingaconstellation
of signs and symptoms. Delirium, falls and incontinence are
examples of geriatric syndromes [4]. We suggest it may be
likewise helpful to recognise sarcopenia as a geriatric syn-
drome because this view promotes its identiﬁcation and
treatmentevenwhenthe exactcauses remain unknown[5,6].
What is the evidence that age-related sarcopenia ﬁts the
current deﬁnition of a geriatric syndrome? Sarcopenia is
prevalent in older populations [7, 8]. Sarcopenia has multiple
contributing factors—the ageing process over the life
course, early life developmental inﬂuences, less-than-opti-
mal diet, bed rest or sedentary lifestyle, chronic diseases
and certain drug treatments [9–11]. Sarcopenia represents
an impaired state of health with a high personal toll—mo-
bility disorders, increased risk of falls and fractures, impaired
ability to perform activities of daily living, disabilities, loss of
independence and increased risk of death [12–16].
European Working Group on Sarcopenia in
Older People
Rationale and methods
While age-related sarcopenia is common and has huge per-
sonal and ﬁnancial costs, sarcopenia still has no broadly
accepted clinical deﬁnition, consensus diagnostic criteria,
International Classiﬁcation of Diseases 9th Revision (ICD-9)
codes or treatment guidelines. To address these shortfalls,
the European Union Geriatric Medicine Society (EUGMS)
decided in 2009 to create a Sarcopenia Working Group that
would develop operational deﬁnitions and diagnostic criteria
for sarcopenia to be used in clinical practice as well as in re-
search studies. Other European scientiﬁc organisations (the
European Society of Clinical Nutrition and Metabolism
[ESPEN], the International Academy of Nutrition and
Aging [IANA] and the International Association of Geron-
tology and Geriatrics—European Region [IAGG-ER]) were
invited to join this group, accepted the request and nomi-
nated representatives who became members of the
Sarcopenia Working Group.
The European Working Group on Sarcopenia in Older
People (EWGSOP, the Sarcopenia Working Group) ﬁrst
met in January 2009, followed by two additional meetings
during the year and by extensive email contacts. Litera-
ture reviews and discussions were guided by the
following questions:
￿ What is sarcopenia?
￿ What parameters define sarcopenia?
￿ What variables will measure them, and what measurement
tools and cut-off points will be used?
￿ How does sarcopenia relate to other diseases/conditions?
The document developed by the Sarcopenia Working
Group was circulated to the Boards of the four participant
organisations (EUGMS, ESPEN, IAGG-ER, IANA) for in-
put, and then revised in accord with review comments, and
sent back to the organisations for ﬁnal endorsement.
What is sarcopenia?
Working definition
Sarcopenia is a syndrome characterised by progressive and
generalised loss of skeletal muscle mass and strength with
a risk of adverse outcomes such as physical disability,
poor quality of life and death [17, 18]. The EWGSOP re-
commends using the presence of both low muscle mass
and low muscle function (strength or performance) for
the diagnosis of sarcopenia. Thus, diagnosis requires docu-
mentation of criterion 1 plus documentation of either
criterion 2 or criterion 3 (Table 1).
The rationale for use of two criteria is: muscle strength
does not depend solely on muscle mass, and the relationship
between strength and mass is not linear [18, 19]. Thus, de-
ﬁning sarcopenia only in terms of muscle mass is too narrow
and may be of limited clinical value. Some have argued that
the term dynapenia is better suited to describe age-asso-
ciated loss of muscle strength and function [20]. However,
sarcopenia is already a widely recognised term, so replacing it
might lead to further confusion.
Mechanisms of sarcopenia
There are several mechanisms that may be involved in the
onset and progression of sarcopenia (Figure 1). These me-
chanisms involve, among others, protein synthesis,
proteolysis, neuromuscular integrity and muscle fat content.
In an individual with sarcopenia, several mechanisms may be
involved, and relative contributions may vary over time. Re-
cognising these mechanisms and their underlying causes is
expected to facilitate design of intervention trials that target
one or more underlying mechanisms.
Table 1. Criteria for the diagnosis of sarcopenia
Diagnosis is based on documentation of criterion 1 plus (criterion 2 or
criterion 3) ............................................................
1. Low muscle mass
2. Low muscle strength
3. Low physical performance
Definition and diagnosis of sarcopenia
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Sarcopenia is a condition with many causes and varying out-
comes. While sarcopenia is mainly observed in older people,
it can also develop in younger adults, as is likewise the case
for dementia and osteoporosis. In some individuals, a clear
and single cause of sarcopenia can be identiﬁed. In other
cases, no evident cause can be isolated. Thus, the categories
of primary sarcopenia and secondary sarcopenia may be use-
ful in clinical practice. Sarcopenia can be considered ‘primary’
(or age-related) when no other cause is evident but ageing it-
self,whilesarcopeniacanbeconsidered‘secondary’whenone
or more other causes are evident (Table 2). In many older
people, the aetiology of sarcopenia is multi-factorial so that
itmaynotbepossibletocharacteriseeachindividualashaving
a primary or secondary condition. This situation is consist-
ent with recognising sarcopenia as a multi-faceted geriatric
syndrome.
Sarcopenia staging, which reﬂects the severity of the
condition, is a concept that can help guide clinical manage-
ment of the condition. EWGSOP suggests a conceptual
staging as ‘presarcopenia’, ‘sarcopenia’ and ‘severe sarcope-
nia’ (Table 3). The ‘presarcopenia’ stage is characterised by
low muscle mass without impact on muscle strength or
physical performance. This stage can only be identiﬁed by
techniques that measure muscle mass accurately and in re-
ference to standard populations. The ‘sarcopenia’ stage is
characterised by low muscle mass, plus low muscle strength
or low physical performance. ‘Severe sarcopenia’ is the stage
identiﬁed when all three criteria of the deﬁnition are met
(low muscle mass, low muscle strength and low physical per-
formance). Recognising stages of sarcopenia may help in
selecting treatments and setting appropriate recovery goals.
Staging may also support design of research studies that
focus on a particular stage or on stage changes over time.
Sarcopenia and other syndromes
Sarcopenia is featured in other syndromes associated with
prominent muscle wasting. The main reason to diﬀerentiate
between them is to encourage research into age-related me-
chanisms of sarcopenia and to guide targeted and
appropriate therapy for each.
Cachexia
‘Cachexia’(Greek‘cac’orbad+‘hexis’orcondition)iswidely
recognised in older adults as severe wasting accompanying
disease states such as cancer, congestive cardiomyopathy
and end-stage renal disease [21]. Cachexia has recently
been deﬁned as a complex metabolic syndrome associated
with underlying illness and characterised by loss of muscle
with or without loss of fat mass [22]. Cachexia is frequent-
ly associated with inﬂammation, insulin resistance, anorexia
and increased breakdown of muscle proteins [23, 24].
Thus, most cachectic individuals are also sarcopenic, but
most sarcopenic individuals are not considered cachectic.
Sarcopenia is one of the elements of the proposed deﬁn-
ition for cachexia [22]. Very recently, a consensus paper
expanding this deﬁnition of cachexia and identifying rele-
vant issues on how to diﬀerentiate cachexia and sarcopenia
was published by ESPEN, one of the EWGSOP-endorsing
societies [25].
Frailty
Frailty is a geriatric syndrome resulting from age-related cu-
mulative declines across multiple physiologic systems, with
impaired homeostatic reserve and a reduced capacity of the
organism to withstand stress, thus increasing vulnerability to
adverse health outcomes including falls, hospitalisation, insti-
tutionalisation and mortality [26, 27]. Fried et al. developed a
phenotypic deﬁnition of frailty based on readily identiﬁable
Figure 1. Mechanisms of sarcopenia.
Table 2. Sarcopenia categories by cause
Primary sarcopenia
Age-related
sarcopenia
No other cause evident except ageing
Secondary sarcopenia
Activity-related
sarcopenia
Can result from bed rest, sedentary lifestyle,
deconditioning or zero-gravity conditions
Disease-related
sarcopenia
Associated with advanced organ failure
(heart, lung, liver, kidney, brain), inflammatory
disease, malignancy or endocrine disease
Nutrition-related
sarcopenia
Results from inadequate dietary intake of energy
and/or protein, as with malabsorption, gastrointestinal
disorders or use of medications that cause anorexia
Table 3. EWGSOP conceptual stages of sarcopenia
Stage Muscle mass Muscle strength Performance ............................................................
Presarcopenia ↓
Sarcopenia ↓↓ Or ↓
Severe sarcopenia ↓↓↓
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414physical aspects; three or more of the following character-
istics support a frailty diagnosis—unintended weight loss,
exhaustion, weakness, slow gait speed and low physical ac-
tivity [27]. Frailty and sarcopenia overlap; most frail older
people exhibit sarcopenia, and some older people with sar-
copenia are also frail. The general concept of frailty,
however, goes beyond physical factors to encompass psy-
chological and social dimensions as well, including
cognitive status, social support and other environmental
factors [26].
Sarcopenic obesity
In conditions such as malignancy, rheumatoid arthritis and
ageing,leanbodymassislostwhilefatmassmaybepreserved
or even increased [28]. This state is called sarcopenic obesity,
and thus the relationship between age-related reduction of
muscle mass andstrength is often independent of body mass.
Ithadlongbeenthoughtthatage-relatedlossofweight,along
with loss of muscle mass, was largely responsible for muscle
weakness in older people [29]. However, it is now clear that
changesinmusclecompositionarealsoimportant,e.g.‘marb-
ling’, or fat inﬁltration into muscle, lowers muscle quality and
work performance [30].
While weight changes vary widely between individuals,
certain patterns of age-related change in body composition
have been observed. In ageing men, the percentage of fat
mass increases initially, then levels oﬀ or decreases. Such
change has been attributed to an accelerated decrease in lean
mass, along with an initial increase and a later decrease in fat
mass [31]. Women show a generally similar pattern [31].
Intramuscular and visceral fat increase with ageing while
subcutaneous fat declines [18, 32, 33].
Identifying sarcopenia in research and
practice
The parameters of sarcopenia are the amount of muscle and
its function. The measurable variables are mass, strength and
physical performance. The challenge is to determine how
best to measure them accurately. It is also important to rec-
ognise change by repeating the same measures over time in
the same individuals. The following sections brieﬂy review
measurement techniques that can be used and discuss their
suitability for research and clinical practice settings.
Assessment techniques
Muscle mass
A wide range of techniques can be used to assess muscle
mass [34]. Cost, availability and ease of use can determine
whether the techniques are better suited to clinical practice
or are more useful for research. Table 4 lists the suggestions
of EWGSOP for use of these techniques in research and in
routine clinical practice.
Bodyimagingtechniques.Threeimagingtechniqueshavebeen
used for estimating muscle mass or lean body mass—com-
puted tomography (CT scan), magnetic resonance imaging
(MRI) and dual energy X-ray absorptiometry (DXA). CT
and MRI are considered to be very precise imaging systems
that can separate fat from other soft tissues of the body, mak-
ing these methods gold standards for estimating muscle mass
in research. High cost, limited access to equipment at some
sites and concerns about radiation exposure limit the use of
these whole-body imaging methods for routine clinical prac-
tice [8]. DXA is an attractive alternative method both for
research and for clinical use to distinguish fat, bone mineral
and lean tissues. This whole-body scan exposes the patient
to minimal radiation. The main drawback is that the equip-
ment is not portable, which may preclude its use in large-
scale epidemiological studies [8].
> CT and MRI are gold standards for estimating muscle
mass in research. DXA is the preferred alternative method
for research and clinical use.
Bioimpedance analysis. Bioimpedance analysis (BIA) esti-
mates the volume of fat and lean body mass. The test
itself is inexpensive, easy to use, readily reproducible and ap-
propriate for both ambulatory and bedridden patients. BIA
measurement techniques, used under standard conditions,
have been studied for >10 years [35], and BIA results under
standard conditions have been found to correlate well with
MRI predictions [36]. Prediction equations have been vali-
dated for multiethnic adults [36] and reference values
established for adult white men and women, including older
subjects [37–39]. Thus, BIA might be a good portable alter-
native to DXA.
> BIA may be considered as a portable alternative
to DXA.
Table 4. Measurements of muscle mass, strength, and
function in research and practice
a
Variable Research Clinical practice ............................................................
Muscle mass Computed tomography (CT) BIA
Magnetic resonance
imaging (MRI)
DXA
Dual energy X-ray
absorptiometry (DXA)
Anthropometry
Bioimpedance analysis (BIA)
Total or partial body
potassium per fat-free
soft tissue
Muscle strength Handgrip strength Handgrip strength
Knee flexion/extension
Peak expiratory flow
Physical performance Short Physical Performance
Battery (SPPB)
SPPB
Usual gait speed
Usual gait speed Get-up-and-go test
Timed get-up-and-go test
Stair climb power test
aPlease refer to the text for a description and references on these measurement
techniques.
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muscle contains >50% of the total body potassium (TBK)
pool, TBK is the classic method for estimation of skeletal
muscle. More recently, partial body potassium (PBK) of
the arm has been proposed as a simpler alternative [40].
PBK of the arm is safe and inexpensive.
> TBK is the classic method for the estimation of skel-
etal muscle, but this method is not used routinely.
Anthropometric measures. Calculations based on mid-upper
arm circumference and skin fold thickness have been used
to estimate muscle mass in ambulatory settings. Calf cir-
cumference correlates positively with muscle mass; calf
circumference <31 cm has been associated with disability
[41]. However, age-related changes in fat deposits and loss
of skin elasticity contribute to errors of estimation in older
people. There are relatively few studies validating anthropo-
metric measures in older and obese people; these and other
confounders make anthropometric measures vulnerable to
error and questionable for individual use [14].
> Anthropometric measures are vulnerable to error
and not recommended for routine use in the diagnosis
of sarcopenia.
Muscle strength
There are fewer well-validated techniques to measure
muscle strength. Although lower limbs are more relevant
than upper limbs for gait and physical function, handgrip
strength has been widely used and is well correlated with
most relevant outcomes. Again, cost, availability and ease
of use can determine whether the techniques are better sui-
ted to clinical practice or are useful for research (Table 4). It
must be remembered that factors unrelated to muscle, e.g.
motivation or cognition, may hamper the correct assessment
of muscle strength.
Handgrip strength. Isometric hand grip strength is strong-
ly related with lower extremity muscle power, knee
extension torque and calf cross-sectional muscle area
[13]. Low handgrip strength is a clinical marker of poor
mobility and a better predictor of clinical outcomes than
low muscle mass [13]. In practice, there is also a linear
relationship between baseline handgrip strength and inci-
dent disability for activities of daily living (ADL) [42].
Muscle strength measures of diﬀerent body compart-
ments are correlated, so when feasible, grip strength
measured in standard conditions with a well-studied
model of a handheld dynamometer with reference popu-
lations can be a reliable surrogate for more complicated
measures of muscle strength in the lower arms or legs.
>G r i ps t r e n g t hi sag o o ds i m p l em e a s u r eo fm u s c l e
strength, and it correlates with leg strength.
Knee flexion/extension. Strength is about the magnitude of
force generation, whereas power is about work rate (work
done per unit time). In healthy older people, power is lost
faster than strength. Both are important, but power is a bet-
ter predictor of certain functional activities [43–45].
The ability of the muscle to generate force can be mea-
sured in several ways. Leg extensor power can be
measured with a commercially available power rig [46].
Strength can be measured isometrically or isokinetically,
the latter being a closer reﬂection of muscle function in
everyday activity. Isometric strength testing of maximal
voluntary contractions can be measured with relatively sim-
ple custom-made equipment. It is usually measured as the
force applied to the ankle, with the subject seated in an
adjustable straight-back chair, the lower leg unsupported
and the knee ﬂexed to 90° [47]. Modern, commercial iso-
kinetic dynamometers allow both isometric and isokinetic
measurements of strength as concentric torque at various
angular velocities [48, 49]. Measurement is feasible in frail
older people [50, 51]. Some data are available for older po-
pulations [52–54], but more are needed from a wider range
of ages and ethnicities. These techniques are suitable for
research studies, but their use in clinical practice is limited
by the need for special equipment and training.
> Knee ﬂexion techniques are suitable for research stud-
ies, but their use in clinical practice is limited by the need for
special equipment and training.
Peak expiratory flow. In people without lung disorders,
peak expiratory ﬂow (PEF) is determined by the strength
of respiratory muscles. PEF is a cheap, simple and widely
accessible technique that has prognostic value [55, 56].
However, research on the use of PEF as a measure of
sarcopenia is limited, so PEF cannot be recommended
as an isolated measure of muscle strength at this time.
> PEF measures the strength of respiratory muscles, but
it cannot be recommended as an isolated measure.
Physical performance
A wide range of tests of physical performance are available,
including the Short Physical Performance Battery (SPPB),
usual gait speed, 6-min walk test and the stair climb power
test (Table 4) [57].
Short Physical Performance Battery. The SPPB evaluates bal-
ance, gait, strength and endurance by examining an
individual’s ability to stand with the feet together in
side-by-side, semi-tandem and tandem positions, time to
walk 8 ft and time to rise from a chair and return to
the seated position ﬁve times [58]. It is a composite of
some separate tests that have also been used individually
in sarcopenia research. It has been recently recommended
by an international working group for use as a functional
outcome measure in clinical trials in frail older persons
[57]. Meaningful changes in the SPPB have been deﬁned
[59, 60]. Thus, the SPPB can be used as a standard
measure of physical performance both for research and
in clinical practice.
> The SPPB, a composite measure of physical per-
formance, is a standard measure both for research and
clinical practice.
Usual gait speed. Buchner et al. ﬁrst recognised a non-linear
relationship between leg strength and usual gait speed; this
A.J. Cruz-Jentoft et al.
416relationship explained how small changes in physiological
capacity may have substantial eﬀects on performance in frail
adults, while large changes in capacity have little or no eﬀect
in healthy adults [61]. Since then, a study by Guralnik et al.
suggested that timed usual gait provides a predictive value
for the onset of disability [62]. Most recently, Cesari et al.
conﬁrmed the importance of gait speed (over a 6-m course)
as a predictor of adverse health events (severe mobility limi-
tation, mortality) but showed that poor performance on
other tests of lower extremity function (standing balance
and time to rise from a chair ﬁve times) had comparable
prognostic value [63]. Usual gait speed can be used in clinical
and research settings [57].
> Gait speed is part of the SPPB, but it can also be used
as a single parameter for clinical practice and research.
Timed get-up-and-go test. The timed get-up-and-go (TGUG)
test measures the time needed to complete a series of func-
tionally important tasks. TGUG requires the subject to
stand up from a chair, walk a short distance, turn around,
return and sit down again. It thus serves as an assessment
of dynamic balance. Balance function is observed and scored
on a ﬁve-point scale [64].
> The TGUG, used in geriatric assessment, can serve as
a performance measurement.
Stair climb power test. The stair climb power test (SCPT)
has been proposed as a clinically relevant measure of leg
power impairment [65]. SCPT results are consistent with
more complex techniques for measuring leg power (double
leg press at 40 and 70% of the one-repetition maximum;
DLP40, DLP70) and performance (SPPB with components
of gait speed chair stand time and standing balance). The
SCPT has been suggested for research settings [65].
> The SCPT may be useful in some research settings.
Defining cut-off points
Cut-oﬀ points depend upon the measurement technique
chosen and on the availability of reference studies. EWG-
SOP recommends use of normative (healthy young adult)
rather than other predictive reference populations, with
cut-oﬀ points at two standard deviations below the mean
reference value. More research is urgently needed in order
to obtain good reference values for populations around
the world.
Various options to deﬁne sub-normal values for sarco-
penia designation have been suggested. The following
section provides some examples of how cut-oﬀ points
have been derived and validated by correlation with other
relevant clinical features.
Baumgartner et al. summed the muscle mass of the four
limbs from a DXA scan as appendicular skeletal muscle
mass (ASM) and deﬁned a skeletal muscle mass index
(SMI) as ASM/height
2 (kg/m
2) [66]. A SMI two standard
deviations below the mean SMI of young male and female
reference groups was deﬁned as the gender-speciﬁcc u t
point for sarcopenia. Deﬁned in this way, sarcopenia was
signiﬁcantly associated with physical disability and was inde-
pendent of ethnicity, age, comorbidity, health behaviours
and fat mass [66]. This method depends upon a measure-
ment of appendicular skeletal muscle mass by DXA or
estimation by BIA [19, 66].
In a cross-sectional survey of people aged ≥18 years in
the USA (n = 14,818 adults >18 years, including n = 4,504
adults >60 years), Janssen et al. [67] also used standard de-
viations to deﬁne sarcopenia, measured in terms of skeletal
muscle index (SMI), where SMI = (skeletal muscle mass/
body mass) × 100. Subjects were considered to have a nor-
mal SMI if their SMI was higher than one standard deviation
below the gender-speciﬁc mean for young adults (aged 18–
39 years). Class I sarcopenia was considered present in sub-
jects whose SMI was within one to two standard deviations
below mean values for young adults, and Class II sarcopenia
was present in subjects whose SMI was below two standard
deviations of young adult values. With these deﬁnitions, sar-
copenia was found to be a relatively common occurrence in
American men and women >60 years; the likelihood of
functional impairment and disability was two times greater
in older men and three times greater in older women with
Class II sarcopenia compared to older people who had a
normal SMI.
Newman et al. [68] performed an observational cohort
study of older people living in the USA (ages 70–79 years,
n = 2,984, 52% women, 41% black). Participants were as-
sessed using DXA and were classiﬁed as sarcopenic using
two diﬀerent approaches to adjust lean mass to body size:
appendicular lean mass divided by height squared (aLM/ht
2)
and appendicular lean mass adjusted for height and body fat
mass (residuals). Because population norms for young adult
blacks and whites are not currently available, the gender-
speciﬁc 20th percentile was arbitrarily chosen as the cut-
oﬀ point for each method. In men, both classiﬁcations of
sarcopenia were associated with smoking, poorer health,
lower activity and impaired lower extremity function. In
women, the classiﬁcation based on both height and fat mass
was more strongly associated with impaired lower extremity
function, while other associations were fewer. As a result of
these ﬁndings, the authors suggested that fat mass should be
considered in estimating prevalence of sarcopenia in women
and in overweight or obese individuals [68].
Norman et al. conducted a study that investigated the
association between BIA and muscle function [69]. The
study investigated the association between resistance and
reactance normalised for height (R/H and Xc/H) and
hand grip strength, an assessment of muscle function.
T h es t u d yi n c l u d e d3 6 3m e na n dw o m e nw i t ham e a n
age of 63.1 years. Patients were grouped in quintiles by
hand grip strength. Results showed that BIA resistance
and reactance normalised for height were both associated
with hand grip strength independent of other predictors of
hand grip strength, such as age and gender. Xc/H was
positively correlated with increases in hand grip strength,
while R/H was negatively correlated with strength; signiﬁ-
cant diﬀerences in hand grip strength by quintile were
associated with vector migration in the RXc graph. The re-
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measure muscle function, which would be particularly use-
ful for patients unable or unwilling to perform grip
strength tests.
Table 5 shows some cut-oﬀ points available from the sar-
copenia literature, based on normative populations when
available or on predictive populations when normative
population data were unavailable.
Sarcopenia screening and assessment
Identifying subjects with sarcopenia, both for clinical prac-
tice and for selection of individuals for clinical trials, seems
to be an important task. The EWGSOP has developed a
s u g g e s t e da l g o r i t h mb a s e do ng a i ts p e e dm e a s u r e m e n ta s
the easiest and most reliable way to begin sarcopenia case
ﬁnding or screening in practice (Figure 2). A cut-oﬀ point
of >0.8 m/s identiﬁes risk for sarcopenia [70].
Treatment outcomes for research
While reduced mobility and functionality are increasingly
prevalent in older people, only a handful of clinical trials
are under way to test potential sarcopenia treatments. The
absence of standardised primary outcomes is a major chal-
lenge for the design of such studies. For intervention trials,
EWGSOP presently recommends three primary outcome
variables—muscle mass, muscle strength and physical per-
Table 5. Diagnosis of sarcopenia: measurable variables and cut-oﬀ points
Criterion Measurement
method
Cut-off points by gender Reference group defined Ref
.............................................................................................................................
Muscle mass DXA Skeletal muscle mass index (SMI) Based on 2 SD below
mean of young adults
(Rosetta Study)
[66]
(Appendicular skeletal muscle mass/height
2)
Men: 7.26 kg/m
2
Women: 5.5 kg/m
2
SMI (ASM/height
2) Based on sex-specific
lowest 20% of study
group (n = 2,976)
[17]
Men: 7.25 kg/m
2
Women: 5.67 kg/m
2
SMI (ASM/height
2) Based on sex-specific
lowest 20% (Health
ABC Study)
[68]
Men: 7.23 kg/m
2
Women: 5.67 kg/m
2
Residuals of linear regression on
appendicular lean mass adjusted for fat
mass as well as height
Based on sex-specific
lowest 20% (Health
ABC Study)
[68]
Men: −2.29
Women: −1.73
BIA SMI using BIA predicted skeletal muscle mass
(SM) equation (SM/height
2)
Based on 2 SD below
mean of young adults
in study group (n = 200)
[8]
Men: 8.87 kg/m
2
Women: 6.42 kg/m
2
SMI using absolute muscle mass,
not appendicular muscle mass
Based on statistical analysis
of NHANES III data on
older (≥60 years) men
and women
[19, 67]
(absolute muscle mass/height
2)
Men:
Severe sarcopenia ≤8.50 kg/m
2
Moderate sarcopenia 8.51–10.75 kg/m
2
Normal muscle ≥10.76 kg/m
2
Women:
Severe sarcopenia ≤5.75 kg/m
2
Moderate sarcopenia 5.76–6.75 kg/m
2
Normal muscle ≥6.76 kg/m
2
Muscle
strength
Handgrip
strength
Men: <30 kg Based on statistical analysis
of study group (n = 1,030)
[13]
Women: <20 kg
Men: Based on quartiles of study group (n = 5,317) [27]
BMI ≤ 24 ≤ 29 kg
BMI 24.1–26 ≤ 30 kg
BMI 26.1–28 ≤ 30 kg
BMI > 28 ≤ 32 kg
Women:
BMI ≤ 23 ≤ 17 kg
BMI 23.1–26 ≤ 17.3 kg
BMI 26.1–29 ≤ 18 kg
BMI > 29 ≤ 21 kg
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ondary and of particular interest in speciﬁcr e s e a r c ha r e a s
and intervention trials.
For each of these outcomes, one or more variables can
be measured. Selection of measurement tools for research
studies will depend on availability, access to data for relevant
reference populations (considering age, gender and ethni-
city), type of study (longitudinal vs cross-sectional), aim of
the study and cost.
Challenges of managing sarcopenia
Depending on the literature deﬁnition used for sarcopenia,
t h ep r e v a l e n c ei n6 0 –7 0 - y e a r - o l d si sr e p o r t e da s5 –13%,
while the prevalence ranges from 11 to 50% in people
>80 years [71]. The number of people around the world
aged ≥60 years was estimated at 600 million in the year
2000, a ﬁgure that is expected to rise to 1.2 billion by 2025
and 2 billion by 2050 [72]. Even with a conservative estimate
of prevalence, sarcopenia aﬀects >50 million people today
and will aﬀect >200 million in the next 40 years.
The impact of sarcopenia on older people is far reaching;
its substantial tolls are measured in terms of morbidity [73],
disability [67], high costs of health care [74] and mortality
[75]. Because the consequences of sarcopenia in older people
are serious and life-changing, health care professionals every-
where are challenged to work together to turn our growing
body of knowledge into actions that will improve the health
and wellbeing of millions of older people around the world.
Once an operational deﬁnition of sarcopenia is adopted
and included in the mainstream of comprehensive geriatric
assessment, the next steps are to deﬁne the natural course of
sarcopenia and to develop and deﬁne eﬀective treatment.
To this end, the ESWGOP committee members and their
allied organisations encourage health care professionals to
seek answers to the following questions:
￿ What is the role of nutrition in prevention and treatment
of age-related sarcopenia? What amounts of macronutri-
ents are needed for older people with or at risk for
sarcopenia, especially protein and specific amino acids?
What micronutrients, e.g. vitamin D, play important roles
in protecting and building lean body mass? And does the
timing for intake of meals and/or dietary supplements
make a difference?
￿ What is the role of physical activity in prevention and
treatment of sarcopenia in older people? What exercises
Table 5. (Continued )
Criterion Measurement
method
Cut-off points by gender Reference group defined Ref
.............................................................................................................................
Physical performance SPPB SPPB ≤8 SPPB score is a summation of scores
on three tests: Balance, Gait Speed and Chair Stand.
Each test is weighted equally with scores between
0 and 4—quartiles generated from Established
Populations for Epidemiologic
Studies of the Elderly (EPESE) data (n = 6,534).
The maximum score on the SPPB is 12
[62]
SPPB 0–6 Low performance
SPPB 7–9 Intermediate performance
SPPB 10–12 High Performance
Gait speed 6-m course Based on statistical analysis of Health
ABC participant data
[63]
GS <1 m/s
6-m course Based on ROC curves analysis of
Health ABC data
[63]
GS <1.175 m/s
15-ft (4.572 m) course Based on quartiles of study group
(n = 5,317)
[27]
Men:
Height ≤ 173 cm ≥ 7 s (GS < 0.65 m/s)
Height > 173 cm ≥ 6 s (GS < 0.76 m/s)
Women:
Height ≤ 159 cm ≥ 7 s (GS < 0.65 m/s)
Height > 159 cm ≥ 6 s (GS < 0.76 m/s)
4-m course Based on statistical analysis of
study group (n = 1,030)
[13]
GS <0.8 m/s
8-ft (2.438 m) course Based on SPPB values
Quartiles of performance:
≤0.43 m/s
0.44–0.60 m/s
0.61–0.77 m/s
≥0.78 m/s
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can older people be enabled to take more habitual physical
activity? For people who have marked physical limitations,
are there alternatives to traditional exercise programmes?
How can nutrition and exercise regimens be combined for
prevention of treatment of sarcopenia?
￿ Do any specific medications have sufficient evidence-
based support for treatment of sarcopenia? If not, what
are the current candidate drugs? What study designs and
outcome measures will be acceptable for drug labelling?
Summary and conclusions
Several European organisations working in nutrition and
geriatric medicine created a joint European Working Group
on Sarcopenia in Older People (EWGSOP). This ﬁnal
EWGSOP paper oﬀers a working deﬁnition of sarcopenia,
summarises what is currently known about underlying me-
chanisms and reviews techniques for measuring variables of
sarcopenia. This paper also oﬀers guidelines for use of these
tools as a way to identify sarcopenia and evaluate treatment
eﬀectiveness, and oﬀers advice about which tools are best
suited for clinical practice and for research studies. Further,
examples of currently used cut-oﬀ points for the diagnosis
of sarcopenia are oﬀered. Based on increased awareness of
sarcopenia in older people and widespread use of tools for
screening and assessment, the ultimate goal is to identify
dietary strategies, lifestyle changes and treatments that can
prevent or delay the onset of sarcopenia.
Key points
￿ Age-related sarcopenia is common and has huge person-
al and financial costs.
￿ This paper presents a clinical definition and consensus
diagnostic criteria for sarcopenia, as developed by the
European Working Group on Sarcopenia in Older
People (EWGSOP) and endorsed by four participating
professional medical societies.
Table 6. Suggested primary and secondary outcome domains
for intervention trials in sarcopenia
Primary outcome domains
￿ Physical performance
￿ Muscle strength
￿ Muscle mass
Secondary outcome domains
￿ Activities of daily living (ADL; basic, instrumental)
￿ Quality of life (QOL)
￿ Metabolic and biochemical markers
￿ Markers of inflammation
￿ Global impression of change by subject or physician
￿ Falls
￿ Admission to nursing home or hospital
￿ Social support
￿ Mortality
* Comorbidity and individual circumstances that may explain each finding must be considered 
+ This algorithm can also be applied to younger individuals at risk
Older subject  
(> 65 years) +
Measure gait 
speed
> 0.8 m/s  ≤ 0.8 m/s 
Measure grip  
strength
Normal  Low 
No sarcopenia 
Measure muscle 
mass
Low  Normal 
No sarcopenia  Sarcopenia 
Figure 2. EWGSOP-suggested algorithm for sarcopenia case ﬁnding in older individuals.
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420￿ The overall goal was to compile a set of tools that
would promote recognition and treatment of age-re-
lated sarcopenia in practice and also encourage
conduct of well-designed research studies of its causes
and consequences.
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